Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
暂无分享,去创建一个
G. von Minckwitz | T. Karn | S. Loibl | A. Ahr | M. Kaufmann | C. Solbach | U. Holtrich | G. Minckwitz | A. Rody | M Kaufmann | G von Minckwitz | M. Munnes | U Holtrich | T Karn | A Rody | R Gätje | A Ahr | C Solbach | K Kourtis | M Munnes | S Loibl | S Kissler | E Ruckhäberle | R. Gätje | S. Kissler | E. Ruckhäberle | K. Kourtis | A. Rody
[1] M. Untch,et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. , 2004, Journal of the National Cancer Institute.
[2] D. Larsimont,et al. HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel , 2004, Breast Cancer Research and Treatment.
[3] M. J. van de Vijver,et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[5] I. Zuna,et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] T. Karn,et al. Gene Expression Profiles of Breast Cancer Obtained from Core Cut Biopsies Before Neoadjuvant Docetaxel, Adriamycin, and Cyclophoshamide Chemotherapy Correlate with Routine Prognostic Markers and Could Be Used to Identify Predictive Signatures , 2005, Zentralblatt fur Gynakologie.
[7] Syed Mohsin,et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.
[8] J. Albanell,et al. Serial Topoisomerase II Expression in Primary Breast Cancer and Response to Neoadjuvant Anthracycline-Based Chemotherapy , 2004, Oncology.
[9] Marek Pawlicki,et al. Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.
[10] Christian A. Rees,et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[11] T. Petit,et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. , 2004, European journal of cancer.
[12] I. Andrulis,et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples , 2004, Genes, chromosomes & cancer.
[13] H. Preisler,et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] T. Karn,et al. Molecular classification of breast cancer patients by gene expression profiling * , 2001, The Journal of pathology.
[15] J. Stec,et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Christine Solbach,et al. Identification of high risk breast-cancer patients by gene expression profiling , 2002, The Lancet.
[17] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[18] Roman Rouzier,et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[19] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[20] L. Liu,et al. DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.